Research programme: liver disorder therapeutics - iECURE
Latest Information Update: 28 Oct 2025
At a glance
- Originator iECURE
- Class Gene therapies; Hepatoprotectants
- Mechanism of Action Gene transference; PCSK9 protein expression modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Liver disorders
Most Recent Events
- 28 Oct 2025 No recent reports of development identified for preclinical development in Liver-disorders in USA (Parenteral)
- 10 Sep 2021 iECURE in-licenses PCSK9-Directed ARCUS Nuclease technology from Precision Biosciences in September 2021
- 10 Sep 2021 Precision BioSciences has patent protection for ARCUS® platform and products worldwide